• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

通过对人、鼠和酵母细胞模型的综合分析来破译 OPA1 突变的致病性。

Deciphering OPA1 mutations pathogenicity by combined analysis of human, mouse and yeast cell models.

机构信息

Unit of Neurology, Department of Biomedical and NeuroMotor Sciences (DIBINEM), University of Bologna, 40139 Bologna, Italy.

Department of Pharmacy and Biotechnology (FABIT), University of Bologna, 40126 Bologna, Italy.

出版信息

Biochim Biophys Acta Mol Basis Dis. 2018 Oct;1864(10):3496-3514. doi: 10.1016/j.bbadis.2018.08.004. Epub 2018 Aug 4.

DOI:10.1016/j.bbadis.2018.08.004
PMID:30293569
Abstract

OPA1 is the major gene responsible for Dominant Optic Atrophy (DOA) and the syndromic form DOA "plus". Over 370 OPA1 mutations have been identified so far, although their pathogenicity is not always clear. We have analyzed one novel and a set of known OPA1 mutations to investigate their impact on protein functions in primary skin fibroblasts and in two "ad hoc" generated cell systems: the MGM1/OPA1 chimera yeast model and the Opa1-/- MEFs model expressing the mutated human OPA1 isoform 1. The yeast model allowed us to confirm the deleterious effects of these mutations and to gain information on their dominance/recessivity. The MEFs model enhanced the phenotypic alteration caused by mutations, nicely correlating with the clinical severity observed in patients, and suggested that the DOA "plus" phenotype could be induced by the combinatorial effect of mitochondrial network fragmentation with variable degrees of mtDNA depletion. Overall, the two models proved to be valuable tools to functionally assess and define the deleterious mechanism and the pathogenicity of novel OPA1 mutations, and useful to testing new therapeutic interventions.

摘要

OPA1 是主要负责显性视神经萎缩(DOA)和综合征型 DOA“plus”的基因。迄今为止,已经发现了超过 370 种 OPA1 突变,尽管它们的致病性并不总是清楚。我们分析了一种新的和一组已知的 OPA1 突变,以研究它们对原代皮肤成纤维细胞以及两种“特别”生成的细胞系统中的蛋白功能的影响:MGM1/OPA1 嵌合酵母模型和表达突变型人 OPA1 同工型 1 的 Opa1-/- MEFs 模型。酵母模型使我们能够确认这些突变的有害影响,并获得关于其显性/隐性的信息。MEFs 模型增强了突变引起的表型改变,与患者观察到的临床严重程度很好地相关,并表明 DOA“plus”表型可能是由线粒体网络碎片化与不同程度 mtDNA 耗竭的组合效应引起的。总的来说,这两个模型被证明是评估和定义新型 OPA1 突变的有害机制和致病性的有价值的工具,并可用于测试新的治疗干预措施。

相似文献

1
Deciphering OPA1 mutations pathogenicity by combined analysis of human, mouse and yeast cell models.通过对人、鼠和酵母细胞模型的综合分析来破译 OPA1 突变的致病性。
Biochim Biophys Acta Mol Basis Dis. 2018 Oct;1864(10):3496-3514. doi: 10.1016/j.bbadis.2018.08.004. Epub 2018 Aug 4.
2
Validation of a MGM1/OPA1 chimeric gene for functional analysis in yeast of mutations associated with dominant optic atrophy.用于在酵母中对与显性视神经萎缩相关的突变进行功能分析的MGM1/OPA1嵌合基因的验证
Mitochondrion. 2015 Nov;25:38-48. doi: 10.1016/j.mito.2015.10.002. Epub 2015 Oct 8.
3
Drug repositioning as a therapeutic strategy for neurodegenerations associated with OPA1 mutations.药物重新定位作为与OPA1突变相关神经退行性疾病的治疗策略。
Hum Mol Genet. 2021 Jan 21;29(22):3631-3645. doi: 10.1093/hmg/ddaa244.
4
Autophagy controls the pathogenicity of OPA1 mutations in dominant optic atrophy.自噬控制着显性视神经萎缩中 OPA1 突变的致病性。
J Cell Mol Med. 2017 Oct;21(10):2284-2297. doi: 10.1111/jcmm.13149. Epub 2017 Apr 4.
5
OPA1 mutations associated with dominant optic atrophy impair oxidative phosphorylation and mitochondrial fusion.与显性遗传性视神经萎缩相关的OPA1突变会损害氧化磷酸化和线粒体融合。
Brain. 2008 Feb;131(Pt 2):352-67. doi: 10.1093/brain/awm335.
6
Mitochondrial dynamics and disease, OPA1.线粒体动力学与疾病,视神经萎缩蛋白1(OPA1)
Biochim Biophys Acta. 2006 May-Jun;1763(5-6):500-9. doi: 10.1016/j.bbamcr.2006.04.003. Epub 2006 Apr 20.
7
model to clarify the pathological significance of OPA1 in autosomal dominant optic atrophy.建立模型以阐明常染色体显性视神经萎缩中 OPA1 的病理意义。
Elife. 2024 Aug 23;12:RP87880. doi: 10.7554/eLife.87880.
8
OPA1: How much do we know to approach therapy?OPA1:我们对治疗方法了解多少?
Pharmacol Res. 2018 May;131:199-210. doi: 10.1016/j.phrs.2018.02.018. Epub 2018 Feb 15.
9
Defective mitochondrial fusion, altered respiratory function, and distorted cristae structure in skin fibroblasts with heterozygous OPA1 mutations.携带杂合OPA1突变的皮肤成纤维细胞中存在线粒体融合缺陷、呼吸功能改变和嵴结构扭曲。
Biochim Biophys Acta. 2012 Oct;1822(10):1570-80. doi: 10.1016/j.bbadis.2012.07.002. Epub 2012 Jul 16.
10
OPA1 mutations induce mitochondrial DNA instability and optic atrophy 'plus' phenotypes.OPA1突变诱导线粒体DNA不稳定及视神经萎缩“加”型表型。
Brain. 2008 Feb;131(Pt 2):338-51. doi: 10.1093/brain/awm298. Epub 2007 Dec 24.

引用本文的文献

1
SARM1 loss protects retinal ganglion cells in a mouse model of autosomal dominant optic atrophy.在常染色体显性遗传性视神经萎缩小鼠模型中,SARM1缺失可保护视网膜神经节细胞。
J Clin Invest. 2025 May 9;135(12). doi: 10.1172/JCI191315. eCollection 2025 Jun 16.
2
Disruption of mitochondrial homeostasis and permeability transition pore opening in OPA1 iPSC-derived retinal ganglion cells.OPA1诱导多能干细胞来源的视网膜神经节细胞中线粒体稳态的破坏和通透性转换孔的开放。
Acta Neuropathol Commun. 2025 Feb 13;13(1):28. doi: 10.1186/s40478-025-01942-z.
3
Severe mitochondrial encephalomyopathy caused by variants in gene.
由基因变异引起的严重线粒体脑肌病。
Front Genet. 2024 Aug 20;15:1437959. doi: 10.3389/fgene.2024.1437959. eCollection 2024.
4
model to clarify the pathological significance of OPA1 in autosomal dominant optic atrophy.建立模型以阐明常染色体显性视神经萎缩中 OPA1 的病理意义。
Elife. 2024 Aug 23;12:RP87880. doi: 10.7554/eLife.87880.
5
Fast and deep phosphoproteome analysis with the Orbitrap Astral mass spectrometer.利用 Orbitrap Astral 质谱仪进行快速而深入的磷酸化蛋白质组分析。
Nat Commun. 2024 Aug 15;15(1):7016. doi: 10.1038/s41467-024-51274-0.
6
The mechanisms of natural products for eye disorders by targeting mitochondrial dysfunction.天然产物通过靶向线粒体功能障碍治疗眼部疾病的机制。
Front Pharmacol. 2024 Apr 25;15:1270073. doi: 10.3389/fphar.2024.1270073. eCollection 2024.
7
OPA1 Dominant Optic Atrophy: Pathogenesis and Therapeutic Targets.OPA1 型显性遗传性视神经萎缩:发病机制与治疗靶点
J Neuroophthalmol. 2023 Dec 1;43(4):464-474. doi: 10.1097/WNO.0000000000001830. Epub 2023 Apr 19.
8
Drug Drop Test: How to Quickly Identify Potential Therapeutic Compounds for Mitochondrial Diseases Using Yeast .药物滴注测试:如何使用酵母快速鉴定潜在的线粒体疾病治疗化合物。
Int J Mol Sci. 2023 Jun 27;24(13):10696. doi: 10.3390/ijms241310696.
9
disease-causing mutants have domain-specific effects on mitochondrial ultrastructure and fusion.致病突变对线粒体超微结构和融合有特定的影响。
Proc Natl Acad Sci U S A. 2023 Mar 21;120(12):e2207471120. doi: 10.1073/pnas.2207471120. Epub 2023 Mar 16.
10
Biallelic Optic Atrophy 1 () Related Disorder-Case Report and Literature Review.双侧视神经萎缩 1 型()相关疾病-病例报告及文献复习。
Genes (Basel). 2022 Jun 2;13(6):1005. doi: 10.3390/genes13061005.